Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer

[1]  W. Zwart,et al.  Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 , 2021, Prostate Cancer and Prostatic Diseases.

[2]  F. Saad,et al.  Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. , 2021 .

[3]  J. Carles,et al.  Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. , 2020, European urology oncology.

[4]  K. Aben,et al.  Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. , 2020, Future oncology.

[5]  F. Saad,et al.  A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Saad,et al.  Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. , 2020, Clinical genitourinary cancer.

[7]  W. Zwart,et al.  A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population , 2019, International journal of cancer.

[8]  A. Yokomizo,et al.  Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases , 2019, International Journal of Clinical Oncology.

[9]  F. Saad,et al.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[10]  E. Andrews,et al.  Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States , 2019, Prostate cancer.

[11]  S. Dizdarevic,et al.  Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  F. Saad,et al.  Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Fanti,et al.  223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience , 2018, Tumori.

[14]  A. Yokomizo,et al.  Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer , 2017, International Journal of Clinical Oncology.

[15]  S. Fosså,et al.  Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. , 2017, European urology.

[16]  L. Eliasson,et al.  Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. , 2017, Clinical therapeutics.

[17]  C. Stief,et al.  Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis , 2017, Radiation oncology.

[18]  C. Sweeney,et al.  Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. , 2016, European urology focus.

[19]  Sender Herschorn,et al.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis , 2016, British Medical Journal.

[20]  C. Parker,et al.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  K. Cooney,et al.  Risk of second primary tumors in men diagnosed with prostate cancer: A population‐based cohort study , 2014, Cancer.

[22]  P. Hoskin,et al.  Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[24]  C. Cleeland.  Brief Pain Inventory Short Form , 2013 .

[25]  S. Nilsson,et al.  High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.

[26]  D. Brenner,et al.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery , 2000, Cancer.

[27]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[28]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.